|Title||Mitochondrial targeting of quinones: therapeutic implications.|
|Publication Type||Journal Article|
|Year of Publication||2007|
|Authors||Cochemé, HM, Kelso, GF, James, AM, Ross, MF, Trnka, J, Mahendiran, T, Asin-Cayuela, J, Blaikie, FH, Manas, A-RB, Porteous, CM, Adlam, VJ, Smith, RAJ, Murphy, MP|
|Date Published||2007 Jun|
|Keywords||Administration, Oral, Animals, Cations, Cell Membrane, Humans, Membrane Potential, Mitochondrial, Membrane Potentials, Mitochondria, Mitochondrial Diseases, Models, Biological, Models, Chemical, Organophosphorus Compounds, Oxygen, Quinones, Ubiquinone|
Mitochondrial oxidative damage contributes to a range of degenerative diseases. Ubiquinones have been shown to protect mitochondria from oxidative damage, but only a small proportion of externally administered ubiquinone is taken up by mitochondria. Conjugation of the lipophilic triphenylphosphonium cation to a ubiquinone moiety has produced a compound, MitoQ, which accumulates selectively into mitochondria. MitoQ passes easily through all biological membranes and, because of its positive charge, is accumulated several hundred-fold within mitochondria driven by the mitochondrial membrane potential. MitoQ protects mitochondria against oxidative damage in vitro and following oral delivery, and may therefore form the basis for mitochondria-protective therapies.
|Grant List||MC_U105663142 / / Medical Research Council / United Kingdom|